ImmunoCellular Therapeutics (IMUC) Reports In-Line Q3 EPS

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c